In vitro efficacy of antiviral compounds against enterovirus D68

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 12, 2015, Pages 7779-7781

  Rhoden, Eric ^a   Zhang, Mingyu ^a,b   Nix, W Allan ^a   Oberste, M Steven ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b HENAN PROVINCIAL CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTIVIRUS AGENT; ARBIDOL; DAS 181; FAVIPIRAVIR; FLUOXETINE; FORMOTEROL FUMARATE; ITRACONAZOLE; MEFLOQUINE; NITAZOXANIDE; OSELTAMIVIR; PLECONARIL; POCAPAVIR; RUPINTRIVIR; UNCLASSIFIED DRUG; V 7404; VAPENDAVIR; PROTEINASE INHIBITOR;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG EFFICACY; EC50; ENTEROVIRUS; ENTEROVIRUS D68; ENTEROVIRUS INFECTION; HUMAN; IN VITRO STUDY; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RHINOVIRUS INFECTION; UNITED STATES; VIRUS STRAIN; DRUG EFFECTS; ENTEROVIRUS D; ENTEROVIRUS INFECTIONS; EPIDEMIC; MICROBIAL SENSITIVITY TEST; RESPIRATORY TRACT INFECTIONS; VIROLOGY; VIRUS CAPSID;

ANTIVIRAL AGENTS; CAPSID; DISEASE OUTBREAKS; ENTEROVIRUS D, HUMAN; ENTEROVIRUS INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; PROTEASE INHIBITORS; RESPIRATORY TRACT INFECTIONS;

EID: 84948147244     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00766-15     Document Type: Article

References (30)

1. Schieble JH, Fox VL, Lennette EH. 1967. A probable new human picornavirus associated with respiratory diseases. Am J Epidemiol 85:297-310.
2. Imamura T, Fuji N, Suzuki A, Tamaki R, Saito M, Aniceto R, Galang H, Sombrero L, Lupisan S, Oshitani H. 2011. Enterovirus 68 among children with severe acute respiratory infection, the Philippines. Emerg Infect Dis 17:1430-1435.
3. Ikeda T, Mizuta K, Abiko C, Aoki Y, Itagaki T, Katsushima F, Katsushima Y, Matsuzaki Y, Fuji N, Imamura T, Oshitani H, Noda M, Kimura H, Ahiko T. 2012. Acute respiratory infections due to enterovirus 68 in Yamagata, Japan between 2005 and 2010. Microbiol Immunol 56: 139-143. http://dx.doi.org/10.1111/j.1348-0421.2012.00411.x.
4. Midgley CM, Jackson MA, Selvarangan R, Turabelidze G, Obringer E, Johnson D, Giles BL, Patel A, Echols F, Oberste MS, Nix WA, Watson JT, Gerber SI. 2014. Severe respiratory illness associated with enterovirus D68 - Missouri and Illinois, 2014. MMWR Morb Mortal Wkly Rep 63: 798-799.
5. Meijer A, Benschop KS, Donker GA, van der Avoort HG. 2014. Continued seasonal circulation of enterovirus D68 in the Netherlands, 2011-2014. Euro Surveill 19:209835. http://www.eurosurveillance.org/View Article.aspx?ArticleId-20935.
6. Drews SJ, Simmonds K, Usman HR, Yee K, Fathima S, Tipples G, Tellier R, Pabbaraju K, Wong S, Talbot J. 2015. Characterization of enterovirus activity, including that of enterovirus D68, in pediatric patients in Alberta, Canada, in 2014. J Clin Microbiol 53:1042-1045. http: //dx.doi.org/10.1128/JCM.02982-14.
7. Cox DW, Bizzintino J, Ferrari G, Khoo SK, Zhang G, Whelan S, Lee WM, Bochkov YA, Geelhoed GC, Goldblatt J, Gern JE, Laing IA, Le Souef PN. 2013. Human rhinovirus species C infection in young children with acute wheeze is associated with increased acute respiratory hospital admissions. Am J Respir Crit Care Med 188:1358-1364. http://dx.doi.org /10.1164/rccm.201303-0498OC.
8. Khetsuriani N, LaMonte A, Oberste MS, Pallansch MA, Centers for Disease Control and Prevention. 2006. Enterovirus surveillance United States, 1970-2005. MMWR Surveill Summ 55:1-20. http://www.cdc.gov /mmwr/preview/mmwrhtml/ss5508a1.htm.
9. Miller EK, Lu X, Erdman DD, Poehling KA, Zhu Y, Griffin MR, Hartert TV, Anderson LJ, Weinberg GA, Hall CB, Iwane MK, Edwards KM. 2007. Rhinovirus-associated hospitalizations in young children. J Infect Dis 195:773-781. http://dx.doi.org/10.1086/511821.
10. Abzug MJ. 2014. The enteroviruses: problems in need of treatments. J Infect 68(Suppl 1):S108-S114. http://dx.doi.org/10.1016/j.jinf.2013.09.020.
11. Imamura T, Okamoto M, Nakakita S, Suzuki A, Saito M, Tamaki R, Lupisan S, Roy CN, Hiramatsu H, Sugawara KE, Mizuta K, Matsuzaki Y, Suzuki Y, Oshitani H. 2014. Antigenic and receptor binding properties of enterovirus 68. J Virol 88:2374-2384. http://dx.doi.org/10.1128/JVI.03070-13.
12. Thibaut HJ, De Palma AM, Neyts J. 2012. Combating enterovirus replication: state-of-the-art on antiviral research. Biochem Pharmacol 83: 185-192. http://dx.doi.org/10.1016/j.bcp.2011.08.016.
13. Oberste MS, Moore D, Anderson B, Pallansch MA, Pevear DC, Collett MS. 2009. In vitro antiviral activity of V-073 against polioviruses. Antimicrob Agents Chemother 53:4501-4503. http://dx.doi.org/10.1128/AAC.00671-09.
14. Binford SL, Maldonado F, Brothers MA, Weady PT, Zalman LS, Meador JW, III, Matthews DA, Patick AK. 2005. Conservation of amino acids in human rhinovirus 3C protease correlates with broad-spectrum antiviral activity of rupintrivir, a novel human rhinovirus 3C protease inhibitor. Antimicrob Agents Chemother 49:619-626. http://dx.doi.org /10.1128/AAC.49.2.619-626.2005.
15. Rhoden E, Liu HM, Wang-Chern SW, Oberste MS. 2013. Anti-poliovirus activity of protease inhibitor AG-7404, and assessment of in vitro activity in combination with antiviral capsid inhibitor compounds. Antiviral Res 98: 186-191. http://dx.doi.org/10.1016/j.antiviral.2013.03.003.
16. Furuta Y, Takahashi K, Fukuda Y, Kuno M, Kamiyama T, Kozaki K, Nomura N, Egawa H, Minami S, Watanabe Y, Narita H, Shiraki K. 2002. In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob Agents Chemother 46:977-981. http://dx.doi.org/10.1128/AAC.46.4.977-981.2002.
17. Moss RB, Hansen C, Sanders RL, Hawley S, Li T, Steigbigel RT. 2012. A phase II study of DAS181, a novel host directed antiviral for the treatment of influenza infection. J Infect Dis 206:1844-1851. http://dx.doi.org /10.1093/infdis/jis622.
18. Ulferts R, van der Linden L, Thibaut HJ, Lanke KH, Leyssen P, Coutard B, De Palma AM, Canard B, Neyts J, van Kuppeveld FJ. 2013. Selective serotonin reuptake inhibitor fluoxetine inhibits replication of human enteroviruses B and D by targeting viral protein 2C. Antimicrob Agents Chemother 57:1952-1956. http://dx.doi.org/10.1128/AAC.02084-12.
19. Bochkov YA, Busse WW, Brockman-Schneider RA, Evans MD, Jarjour NN, McCrae C, Miller-Larsson A, Gern JE. 2013. Budesonide and formoterol effects on rhinovirus replication and epithelial cell cytokine responses. Respir Res 14:98. http://dx.doi.org/10.1186/1465-9921-14-98.
20. Strating JR, van der Linden L, Albulescu L, Bigay J, Arita M, Delang L, Leyssen P, van der Schaar HM, Lanke KH, Thibaut HJ, Ulferts R, Drin G, Schlinck N, Wubbolts RW, Sever N, Head SA, Liu JO, Beachy PA, De Matteis MA, Shair MD, Olkkonen VM, Neyts J, van Kuppeveld FJ. 2015. Itraconazole inhibits enterovirus replication by targeting the oxysterolbinding protein. Cell Rep 10:600-615. http://dx.doi.org/10.1016/j.celrep.2014.12.054.
21. Brickelmaier M, Lugovskoy A, Kartikeyan R, Reviriego-Mendoza MM, Allaire N, Simon K, Frisque RJ, Gorelik L. 2009. Identification and characterization of mefloquine efficacy against JC virus in vitro. Antimicrob Agents Chemother 53:1840-1849. http://dx.doi.org/10.1128/AAC.01614-08.
22. Rossignol JF. 2014. Nitazoxanide: a first-in-class broad-spectrum antiviral agent. Antiviral Res 110:94-103. http://dx.doi.org/10.1016/j.antiviral.2014.07.014.
23. Brown BA, Nix WA, Sheth M, Frace M, Oberste MS. 2014. Seven strains of enterovirus D68 detected in the United States during the 2014 severe respiratory disease outbreak. Genome Announc 2:e01201-14.
24. Gao Q, Yuan S, Zhang C, Wang Y, Wang Y, He G, Zhang S, Altmeyer R, Zou G. 2015. Discovery of itraconazole with broad-spectrum in vitro antienterovirus activity that targets nonstructural protein 3A. Antimicrob Agents Chemother 59:2654-2665. http://dx.doi.org/10.1128/AAC.05108-14.
25. Pevear DC, Tull TM, Seipel ME, Groarke JM. 1999. Activity of pleconaril against enteroviruses. Antimicrob Agents Chemother 43:2109-2115.
26. Liu Y, Sheng J, Fokine A, Meng G, Shin WH, Long F, Kuhn RJ, Kihara D, Rossmann MG. 2015. Structure and inhibition of EV-D68, a virus that causes respiratory illness in children. Science 347:71-74. http://dx.doi.org /10.1126/science.1261962.
27. Collett MS, Neyts J, Modlin JF. 2008. A case for developing antiviral drugs against polio. Antiviral Res 79:179-187. http://dx.doi.org/10.1016 /j.antiviral.2008.04.002.
28. De Palma AM, Pürstinger G, Wimmer E, Patick AK, Andries K, Rombaut B, De Clercq E, Neyts J. 2008. Potential use of antiviral agents in polio eradication. Emerg Infect Dis 14:545-551. http://dx.doi.org/10.3201 /eid1404.070439.
29. Belser JA, Lu X, Szretter KJ, Jin X, Aschenbrenner LM, Lee A, Hawley S, Kim do H, Malakhov MP, Yu M, Fang F, Katz JM. 2007. DAS181, a novel sialidase fusion protein, protects mice from lethal avian influenza H5N1 virus infection. J Infect Dis 196:1493-1499. http://dx.doi.org/10.1086/522609.
30. Midgley CM, Watson JT, Nix WA, Curns AT, Rogers SL, Brown BA, Conover C, Dominguez SR, Feikin DR, Gray S, Hassan F, Hoferka S, Jackson MA, Johnson D, Leshem E, Miller L, Bezdeck Nichols J, Nyquist AC, Obringer E, Patel A, Patel M, Rha B, Schneider E, Schuster JE, Selvarangan R, Seward JF, Turabelidze G, Oberste MS, Pallansch MA, Gerber SI, EV-D68 Working Group. Lancet Respir Med, in press.